Almirall's Ilumetri (tildrakizumab) Receives NICE's Provisional Approval for Moderate-To-Severe Plaque Psoriasis
Shots:
- The approval is based on P-III reSURFACE 1 & reSURFACE 2 studies assessing Ilumetri (tildrakizumab) in 1-800 patients with moderate-to-severe plaque psoriasis across 200 sites WW
- reSURFACE 1 & reSURFACE 2 studies result: @12wks. PASI 75 (75%); @28wks. PASI 90 (54%)- PASI 100 (29%); well tolerated; low AEs & discontinuation rates
- Ilumetri (tildrakizumab- SC- 100mg- q3mt) is a mAb targeting interleukin IL 23 p19 with its expected NICE approval in Apr’19. It has also received EU approval in Sept’18- codeveloped & co commercialize by Almirall & Sun Pharma under an agreement July’16
Ref: Almirall | Image: Okdiario
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com